<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04429139</url>
  </required_header>
  <id_info>
    <org_study_id>2011MEKY0015</org_study_id>
    <nct_id>NCT04429139</nct_id>
  </id_info>
  <brief_title>Photodynamic Therapy With Visudyne for Human Retinoblastoma: A Preliminary Study</brief_title>
  <official_title>Photodynamic Therapy With Visudyne for Human Retinoblastoma: A Preliminary Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effectiveness and safety profiles of photodynamic therapy (PDT) for the
      treatment of human retinoblastoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retinoblastoma is the commonest primary intraocular malignancy in infancy and early
      childhood. Ophthalmologist are trying to seek other more safe and effective treatment
      modalities to well control the tumor and preserve the visual function. Photodynamic therapy
      (PDT) is a potentially therapeutic approach for retinoblastoma which has been underestimated.
      In this study, we are gonging to investigate the the effectiveness and safety profiles of
      photodynamic therapy (PDT) for the treatment of human retinoblastoma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2011</start_date>
  <completion_date type="Actual">May 30, 2020</completion_date>
  <primary_completion_date type="Actual">May 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>eye enucleation</measure>
    <time_frame>3 years</time_frame>
    <description>the rate of eye enucleation of patients with retinoblastoma in different groups</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Retinoblastoma</condition>
  <arm_group>
    <arm_group_label>PDT treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All the patients received once PDT with Visudyne® as the initial treatment. Rescue treatment with systemic chemotherapy would be given to patients if tumors were insensitive to PDT treatment, the tumors became larger, or disease relapse.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>photodynamic therapy</intervention_name>
    <description>PDT with Visudyne® was performed under general anesthesia according to the standard TAP study with some modifications: Verteporfin (6 mg/m2, Visudyne®; Novartis International AG, Basel, Switzerland) was injected intravenously with a standard 10-min infusion followed by followed by application of diode laser (Opal Photoactivator; Coherent Medical Group, Santa Clara, USA) (689 nm, 50 J/cm2, 600 mW/cm2) for 200 seconds to generate 120 J/cm2.</description>
    <arm_group_label>PDT treatment group</arm_group_label>
    <other_name>systemic chemotherapy</other_name>
    <other_name>Laser photocoagulation</other_name>
    <other_name>Cryotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with intraocular retinoblastoma of Group A-D

        Exclusion Criteria:

          -  (1) patients with intraocular retinoblastoma of group E; (2) patients with extraocular
             spread; (3); media opacities such as corneal opacity, significant cataract, or
             vitreous hemorrhage obscuring fundus examination; (4) patients who were allergic to
             verteporfin or other benzoporphyrin derivatives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kunbei Lai</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 10, 2020</study_first_submitted>
  <study_first_submitted_qc>June 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2020</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Jin Chen-jin</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Photodynamic therapy</keyword>
  <keyword>Retinoblastoma</keyword>
  <keyword>Visudyne</keyword>
  <keyword>Verteporfin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinoblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

